Drug Delivery | Ophthalmology Innovation Source

What’s New with Three Sustained-Release Drug Platforms

Most ophthalmic drugs are delivered by topical application or direct injection into the vitreous, and many are limited by difficulties in sustaining therapeutic drug levels or by problems with patient adherence. As effective as topical drops are for delivering medication to the eye, they are wholly dependent on patient adherence. Even patients with potentially blinding…

Highlights from AGS: New Surgical Devices, Novel Therapeutics

This year’s American Glaucoma Society annual meeting feted novel medications designed to lower intraocular pressure (IOP) in patients with glaucoma. To date, available medications and surgery are designed to treat one of the primary risk factors – elevated IOP. But they are not designed to directly target the underlying degeneration that’s causing the vision loss.…

How MIGS is Remaking the Glaucoma Market

Glaucoma is a chronic degenerative disease whose incidence increases significantly with age. According to the World Health Organization, it is the second leading cause of blindness in the world. Estimates put the total number of suspected cases of glaucoma at over 60 million worldwide. Glaucoma medications, which generate about $5 billion in annual sales globally,…

EyeGate Finds New Paths to Dollars, Deal

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 072″] EyeGate Pharmaceuticals had hit a wall. Its venture investors were tapped out, and the company needed capital to continue running clinical trials on its lead product. CEO Stephen From turned to the public markets, leading the company through a unique – and small IPO. With $4 million from the offering,…

Opthea Taking New Approach to Combat Wet AMD

Megan Baldwin, PhD, Managing Director and CEO of Opthea, gives an update on OPT-302, a soluble receptor consisting of the first three extracellular domains of human VEGFR-3 linked to the Fc region of hIgG1. Baldwin explains how OPT-302 potently and specifically blocks VEGF-C and VEGF-D from binding and activating VEGFR-2 and VEGFR-3, making it a…

Ocular Therapeutix Taking Aim at Allergy Market

Amar Sawhney, PhD, Chairman, Chairman, President & CEO of Ocular Therapeutics, touts the performance of Dextenza, the company’s anti-allergy medication. Instead of taking one drop a day, allergy sufferers just need one treatmet of Dextenza to survive a whole season. Speaking With: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since…

Allegro Ophthalmics

Allegro Ophthalmics describes itself as a “mid-stage biotech company.” Its lead agent, Luminate, is an integrin peptide therapy that is the subject of a number of Phase II trials, including a trial that released topline data in September on its efficacy in vitreomacular traction. Other Phase IIb trials in progress are investigating Luminate for the…

Vision Medicines

Vision Medicines is working on developing two agents for the treatment of ocular diseases: VM100 for treatment of geographic atrophy and intermediate age-related macular degeneration (AMD), and VM200 for treatment of Stargardt disease. VM100 is a monoclonal antibody whose mechanism of action is to clear retinal amyloid (A beta) and its complement. VM100 can be…

Inotek Pharmaceuticals

David P. Southwell, president and CEO of Inotek Pharmaceuticals, spelled out the focus of his clinical-stage biopharmaceutical firm in no uncertain terms at OIS@AAO. “Inotek is focused on glaucoma,” he said. “Clearly the optimal eyedrop to treat glaucoma would be one that both lowers intraocular pressure (IOP) in a well-tolerated fashion and is also neuroprotective.”…

Translatum Medicus

Presenter: Shelley Boyd, MD, FRCSC Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina and founding President & CSO of Translatum Medicus Inc(TMi). She trained at the University of Toronto, with fellowships at Moorfields Eye Hospital, UK and the Scripps Research Institute, California. View Full Profile

Circadian Technologies (Opthea)

Participant: Megan Baldwin Dr. Megan Baldwin is CEO/Managing Director of Circadian Technologies (Opthea) and has over 19 years of experience in preclinical and clinical development of therapies for cancer and eye diseases. View Full Profile

PanOptica

Participant: Paul Chaney Paul G. Chaney is Co-Founder, President & CEO of PanOptica Inc., a biopharma company developing PAN-90806, a novel topical anti-VEGF treatment for neovascular eye diseases. View Full Profile